File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Seven-day rifabutin containing triple therapy versus seven-day levofloxacin containing quadruple therapy as second-line treatment for Helicobacter pylori in Chinese patients: an open label, randomized trial

TitleSeven-day rifabutin containing triple therapy versus seven-day levofloxacin containing quadruple therapy as second-line treatment for Helicobacter pylori in Chinese patients: an open label, randomized trial
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
The 2015 Digestive Disease Week (DDW 2015), Washington, DC., 16-19 May 2015. In Gastroenterology, 2015, v. 148 n. 4 suppl. 1, p. S149, abstract no. 771 How to Cite?
AbstractINTRODUCTION: Rifabutin containing triple therapy (RIF) and levofloxacin containing quadruple therapy (QUAD) has been used as rescue therapy for resistant H. pylori infection. We compared the efficacy and tolerability of 7-day RIF with 7-day QUAD as second-line treatment for H. pylori infection. Levofloxacin was used instead of bismuth subcitrate for the quadruple therapy, as bismuth is no longer available in Hong Kong. METHODS: Patients who have failed the triple therapy (esomeprazole, amoxicillin, and clarithromycin) and remained H. pyloripositive were randomly assigned to receive either 7-day RIF (esomeprazole, rifabutin and amoxicillin) or QUAD (esomeprazole, levofloxacin, tetracycline and metronidazole) treatments. H. pylori eradication was confirmed by urea breath test at 8 weeks. The primary outcome was the eradication rates by intention-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: One hundred and fifty-one patients were randomized to receive either RIF or QUAD. The PP eradication rate of the RIF and QUAD groups were 89.3% and 95.6%, respectively (P = 0.16). Base on ITT analysis, the corresponding eradication rate was 88.2% and 90.7% (P = 0.62). One patient (1.3%) in the RIF and seven (9.3%) patients in the QUAD failed to complete the treatment regime. The overall incidences of adverse events were higher in the QUAD (30.7%) than in the RIF (15.8%) group (P = 0.03). CONCLUSION: Seven-day rifabutin containing triple therapy and levofloxacin containing quadruple therapy are both highly effective and should be considered as second-line treatment for resistant H. pylori infection.
DescriptionOral Presentation
Persistent Identifierhttp://hdl.handle.net/10722/217522
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorHung, IFN-
dc.contributor.authorLiu, SHK-
dc.contributor.authorTan, VP-
dc.contributor.authorHsu, ASJ-
dc.contributor.authorSeto, WK-
dc.contributor.authorTong, TSM-
dc.contributor.authorLeung, WK-
dc.date.accessioned2015-09-18T06:02:17Z-
dc.date.available2015-09-18T06:02:17Z-
dc.date.issued2015-
dc.identifier.citationThe 2015 Digestive Disease Week (DDW 2015), Washington, DC., 16-19 May 2015. In Gastroenterology, 2015, v. 148 n. 4 suppl. 1, p. S149, abstract no. 771-
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/217522-
dc.descriptionOral Presentation-
dc.description.abstractINTRODUCTION: Rifabutin containing triple therapy (RIF) and levofloxacin containing quadruple therapy (QUAD) has been used as rescue therapy for resistant H. pylori infection. We compared the efficacy and tolerability of 7-day RIF with 7-day QUAD as second-line treatment for H. pylori infection. Levofloxacin was used instead of bismuth subcitrate for the quadruple therapy, as bismuth is no longer available in Hong Kong. METHODS: Patients who have failed the triple therapy (esomeprazole, amoxicillin, and clarithromycin) and remained H. pyloripositive were randomly assigned to receive either 7-day RIF (esomeprazole, rifabutin and amoxicillin) or QUAD (esomeprazole, levofloxacin, tetracycline and metronidazole) treatments. H. pylori eradication was confirmed by urea breath test at 8 weeks. The primary outcome was the eradication rates by intention-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: One hundred and fifty-one patients were randomized to receive either RIF or QUAD. The PP eradication rate of the RIF and QUAD groups were 89.3% and 95.6%, respectively (P = 0.16). Base on ITT analysis, the corresponding eradication rate was 88.2% and 90.7% (P = 0.62). One patient (1.3%) in the RIF and seven (9.3%) patients in the QUAD failed to complete the treatment regime. The overall incidences of adverse events were higher in the QUAD (30.7%) than in the RIF (15.8%) group (P = 0.03). CONCLUSION: Seven-day rifabutin containing triple therapy and levofloxacin containing quadruple therapy are both highly effective and should be considered as second-line treatment for resistant H. pylori infection.-
dc.languageeng-
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro-
dc.relation.ispartofGastroenterology-
dc.rights© <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleSeven-day rifabutin containing triple therapy versus seven-day levofloxacin containing quadruple therapy as second-line treatment for Helicobacter pylori in Chinese patients: an open label, randomized trial-
dc.typeConference_Paper-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailTan, VP: vpytan@hku.hk-
dc.identifier.emailHsu, ASJ: axelhsu@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailTong, TSM: tongsma@hkucc.hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityTan, VP=rp01458-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.hkuros253262-
dc.identifier.volume148-
dc.identifier.issue4, suppl. 1-
dc.identifier.spageS149, abstract no. 771-
dc.identifier.epageS149, abstract no. 771-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats